Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

ADVERTISEMENT

Supportive Care Resource Center

News
Patients Often Favor Receiving Information About Cancer Therapy From the Oncologist
02/14/2023

Yvette C Terrie

Yvette C Terrie
According to findings from a patient-completed questionnaire published in the Journal of Cancer Education, among oncology patients, many favored receiving pertinent information directly from the oncologist regarding various facets of...
According to findings from a patient-completed questionnaire published in the Journal of Cancer Education, among oncology patients, many favored receiving pertinent information directly from the oncologist regarding various facets of...
According to findings from a...
02/14/2023
Journal of Clinical Pathways
Trending From ACCC
Improving the Care of Patients With Advanced Nonmelanoma Skin Cancers
02/06/2023
Association of Community Cancer Centers
In 2022, the Association of Community Cancer Centers (ACCC) developed the Advanced Non-Melanoma Skin Cancers Visiting Experts Program to educate multidisciplinary providers through interactive, virtual discussions on effective practices for...
In 2022, the Association of Community Cancer Centers (ACCC) developed the Advanced Non-Melanoma Skin Cancers Visiting Experts Program to educate multidisciplinary providers through interactive, virtual discussions on effective practices for...
In 2022, the Association of...
02/06/2023
Journal of Clinical Pathways
Research Reports
Post–COVID-19 Syndrome Clinical Pathway for the US Veterans Health Administration
02/06/2023
Claudia L Campos, MD
Cristina Nguyen, BS
Kristina Crothers, MD
Omar Awan, MD
Francis J Miller Jr, MD
Courtney Sedillo, MSN, FNP-C
Johnson Vachachira, NP
Carrie B May, PsyD
Allison M Gustavson, DPT, PhD
Jacob B Lindheimer, PhD
Lindheimer et al summarize the stepwise diagnostic approach for patients presenting with PCS dyspnea and/or cough in primary care and highlight teleconsultation and telerehabilitation as opportunities to reach those in rural areas or with...
Lindheimer et al summarize the stepwise diagnostic approach for patients presenting with PCS dyspnea and/or cough in primary care and highlight teleconsultation and telerehabilitation as opportunities to reach those in rural areas or with...
Lindheimer et al summarize the...
02/06/2023
Journal of Clinical Pathways
Debra Patt, MD, MPH, MBA
Videos
Reducing Disparities Through the Implementation of Digital Health Solutions in the Community Oncology Practice Setting
08/12/2022
Debra Patt, MD, MPH, MBA, implemented digital health solutions across a large practice, aiming to better understand which patient populations use these tools over time and characterize engagement across populations to enhance clinical...
Debra Patt, MD, MPH, MBA, implemented digital health solutions across a large practice, aiming to better understand which patient populations use these tools over time and characterize engagement across populations to enhance clinical...
Debra Patt, MD, MPH, MBA,...
08/12/2022
Journal of Clinical Pathways
Research Reports
Quality Measure Concepts to Fill Gaps in Assessing Oral Oncolytic Adherence: A Multistakeholder Measurement Strategy
06/16/2022
Michael Reff, RPh, MBA
David Blaisdell, BA
Leigh Boehmer, PharmD
Sandra Kurtin, PhD
Shelley Fuld Nasso, MPP
Rachael Peroutky, MSPH
Katie Schultz, MSPH
Tom Valuck, MD, JD
A multistakeholder workgroup of oncology and quality measurement experts explored gaps in quality measures focused on oral oncolytic adherence and identified, prioritized, and refined measure concepts for further development.
A multistakeholder workgroup of oncology and quality measurement experts explored gaps in quality measures focused on oral oncolytic adherence and identified, prioritized, and refined measure concepts for further development.
A multistakeholder workgroup of...
06/16/2022
Journal of Clinical Pathways
Conference Coverage
Real-World Utilization and Comparative Effectiveness of Treatment Options for Cancer–Associated Venous Thromboembolism
06/04/2022

Janelle Bradley

Janelle Bradley
In the real-world setting, patients with cancer–associated venous thromboembolism remain on anticoagulation for a short period of time and DOACs and warfarin may be associated with better compliance than low molecular weight heparin.
In the real-world setting, patients with cancer–associated venous thromboembolism remain on anticoagulation for a short period of time and DOACs and warfarin may be associated with better compliance than low molecular weight heparin.
In the real-world setting,...
06/04/2022
Journal of Clinical Pathways
News
Immune Checkpoint Inhibitors May Have Been Used Inappropriately in Half of Study Patients with Advanced Cancer Who Were Near the End of Life
05/18/2022

Ellen Kurek

Ellen Kurek
Immune checkpoint inhibitors (ICIs) have been shown to extend progression-free survival and overall survival in patients with a variety of cancers, leading to increases in the systemic treatment of patients with advanced cancer who are near...
Immune checkpoint inhibitors (ICIs) have been shown to extend progression-free survival and overall survival in patients with a variety of cancers, leading to increases in the systemic treatment of patients with advanced cancer who are near...
Immune checkpoint inhibitors...
05/18/2022
Journal of Clinical Pathways
Rachael Peroutky, MSPH
Quality Outlook
Nurses are Burned Out. Can Quality Measures Help?
04/11/2022

Rachael Peroutky, MSPH, Tess Donckels, MSPH, Sarena Ho, Katie Schultz, Sara Khan Shirsekar; Blog Editor: Tom Valuck, MD, JD 

Rachael Peroutky, MSPH, Tess Donckels...
This blog addresses "nurse burnout," the occupational phenomena that many nurses face, and suggests that quality measurement strategies for nurse burnout may be most effective in the hospital setting since evidence tying burnout to patient...
This blog addresses "nurse burnout," the occupational phenomena that many nurses face, and suggests that quality measurement strategies for nurse burnout may be most effective in the hospital setting since evidence tying burnout to patient...
This blog addresses "nurse...
04/11/2022
Journal of Clinical Pathways
Research Reports
Factors Associated With Poor Outcomes in Patients who Receive Cancer Directed Therapy at the End of Life
02/15/2022
Yasmine Anouty, PharmD
Ila M. Saunders, PharmD, BCOP
Shanna Block, PharmD, BCOP
Katherine Medley, PharmD
Rabia S. Atayee, PharmD, BCPS
Megan Wall, MS
Alison Wall, MS
Carolyn Mulroney, MD
Janine Martino, PharmD, BCOP, APh
Yasmine Anouty, PharmD, and colleagues discern factors that may be associated with poor outcomes in adult patients who received intravenous cancer-directed therapy in the last 30 days of life.
Yasmine Anouty, PharmD, and colleagues discern factors that may be associated with poor outcomes in adult patients who received intravenous cancer-directed therapy in the last 30 days of life.
Yasmine Anouty, PharmD, and...
02/15/2022
Journal of Clinical Pathways

Expert Insights

Debra Patt, MD, MPH, MBA
Videos
Reducing Disparities Through the Implementation of Digital Health Solutions in the Community Oncology Practice Setting
08/12/2022
Debra Patt, MD, MPH, MBA, implemented digital health solutions across a large practice, aiming to better understand which patient populations use these tools over time and characterize engagement across populations to enhance clinical...
Debra Patt, MD, MPH, MBA, implemented digital health solutions across a large practice, aiming to better understand which patient populations use these tools over time and characterize engagement across populations to enhance clinical...
Debra Patt, MD, MPH, MBA,...
08/12/2022
Journal of Clinical Pathways
Building Clinical Pathways With an Emphasis on Specific Community Needs
Interview
Building Clinical Pathways With an Emphasis on Specific Community Needs
12/16/2020
Carla Baker, RN, discusses the Memphis Breast Cancer Consortium, including the organization's mission, structure, and approach to pathways design.
Carla Baker, RN, discusses the Memphis Breast Cancer Consortium, including the organization's mission, structure, and approach to pathways design.
Carla Baker, RN, discusses the...
12/16/2020
Journal of Clinical Pathways
PCORI to Incorporate Cost But Not Cost-Effectiveness in its New Principles
Healthcare Economist
PCORI to Incorporate Cost But Not Cost-Effectiveness in its New Principles
10/09/2020
Jason Shafrin, PhD, highlights the Patient-Centered Outcomes Research Institute's (PCORI) Proposed “Principles” for the Consideration of the Full Range of Outcomes Data.
Jason Shafrin, PhD, highlights the Patient-Centered Outcomes Research Institute's (PCORI) Proposed “Principles” for the Consideration of the Full Range of Outcomes Data.
Jason Shafrin, PhD, highlights...
10/09/2020
Journal of Clinical Pathways
Integrating Prehabilitation, Rehabilitation, and Prospective Surveillance Into the Cancer Care Continuum
Videos
Integrating Prehabilitation, Rehabilitation, and Prospective Surveillance Into the Cancer Care Continuum
10/08/2020
10/08/2020
Journal of Clinical Pathways
Guest Blog
Achieving “Victory” Through Holistic Palliative Care
07/03/2019

Adil Akhtar, MD

Adil Akhtar, MD
Adil Akhtar, MD, offers the perspective that, if patients can learn to see their bodies as more important than their cancer, they will be more likely to agree to and continue palliative care.
Adil Akhtar, MD, offers the perspective that, if patients can learn to see their bodies as more important than their cancer, they will be more likely to agree to and continue palliative care.
Adil Akhtar, MD, offers the...
07/03/2019
Journal of Clinical Pathways
Guest Blog
Pharmacogenomics: Preemptive Testing Decisions Reach Across the Care Team
01/07/2019

Kandace Schuft, PharmD

Kandace Schuft, PharmD
Kandace Schuft, PharmD, discusses the challenges of implementing pharmacogenomics testing in actual practice and determining its place in the workflow of multiple care teams.
Kandace Schuft, PharmD, discusses the challenges of implementing pharmacogenomics testing in actual practice and determining its place in the workflow of multiple care teams.
Kandace Schuft, PharmD,...
01/07/2019
Journal of Clinical Pathways
Guest Blog
Why Palliative Care is More Than Just Care for the Dying
04/28/2018

Tim Holder, MD

Tim Holder, MD
Many physicians still mistakenly believe that hospice and palliative medicine are one and the same, according to Timothy W Holder, MD, medical director, supportive care and survivorship, Cancer Treatment Centers of America.
Many physicians still mistakenly believe that hospice and palliative medicine are one and the same, according to Timothy W Holder, MD, medical director, supportive care and survivorship, Cancer Treatment Centers of America.
Many physicians still mistakenly...
04/28/2018
Journal of Clinical Pathways
Lalan Wilfong, MD
Videos
Balancing the Benefits and Risks of Value-Based Care Arrangements
05/16/2024
Lalan Wilfong, MD
Lalan Wilfong, MD, discusses his key takeaways from the Community Oncology Conference session on defining value-based care in oncology.
Lalan Wilfong, MD, discusses his key takeaways from the Community Oncology Conference session on defining value-based care in oncology.
Lalan Wilfong, MD, discusses his...
05/16/2024
Journal of Clinical Pathways
BDHC thumbnail
Breaking Down Health Care
The Bear: Why Does Health Care Cost So Much? (Part 1)
05/06/2024

Featuring Michael Kolodziej, MD, and John Hennessy, MBA

Featuring Michael Kolodziej, MD, and ...
In part one of this two-part Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, dig into two of the main stakeholders in health care costs: hospitals and health insurance companies. They discuss how these...
In part one of this two-part Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, dig into two of the main stakeholders in health care costs: hospitals and health insurance companies. They discuss how these...
In part one of this two-part...
05/06/2024
Cancer Care Business Exchange
Julia Morton
Videos
The Impact of Technology at the Point of Care in Community Practice
05/01/2024
Julia Morton, senior vice president and general manager at Flatiron Health, talks about how recent developments in technology have impacted point-of-care solutions in community oncology.
Julia Morton, senior vice president and general manager at Flatiron Health, talks about how recent developments in technology have impacted point-of-care solutions in community oncology.
Julia Morton, senior vice...
05/01/2024
Journal of Clinical Pathways
JCP Flatiron Roundtable 1 Thumbnail
Videos
Oncology Care Pathways: Perspectives on Strategies and Best Practices
05/01/2024

Featuring Gordon Kuntz; Jeremy Drainville; James Hamrick, MD; Larry Shulman, MD; Bryan Loy, MD

Featuring Gordon Kuntz; Jeremy Drainv...
In this roundtable, participants discuss how to develop and implement clinical pathways at cancer centers. This includes integrating both the latest clinical evidence and payer contract requirements to develop the most efficient clinical...
In this roundtable, participants discuss how to develop and implement clinical pathways at cancer centers. This includes integrating both the latest clinical evidence and payer contract requirements to develop the most efficient clinical...
In this roundtable, participants...
05/01/2024
Journal of Clinical Pathways
Michael Serzan, MD
Videos
Recent Advancements in the Treatment of Renal Cell Carcinoma
04/24/2024

Featuring Michael Serzan, MD, Dana-Farber Cancer Institute

Featuring Michael Serzan, MD, Dana-Fa...
Michael Serzan, MD, highlights some of the latest advancements in the treatment of renal cell carcinoma.
Michael Serzan, MD, highlights some of the latest advancements in the treatment of renal cell carcinoma.
Michael Serzan, MD, highlights...
04/24/2024
Journal of Clinical Pathways
Kerry Rogers, MD
Interview
Venetoclax Plus Ibrutinib Combination Therapy for Treating Patients With CLL With Resistance Mutations
04/19/2024

Featuring Kerry Rogers, MD, The Ohio State University

Featuring Kerry Rogers, MD, The Ohio ...
Kerry Rogers, MD, The Ohio State University, discusses results from her study on how Bruton tyrosine kinase (BTK) inhibitors ibrutinib and venetoclax could help eliminate molecular resistance in patients with CLL who have resistance mutations.
Kerry Rogers, MD, The Ohio State University, discusses results from her study on how Bruton tyrosine kinase (BTK) inhibitors ibrutinib and venetoclax could help eliminate molecular resistance in patients with CLL who have resistance mutations.
Kerry Rogers, MD, The Ohio State...
04/19/2024
Journal of Clinical Pathways
Rose Gerber, MS
Videos
Becoming a Patient Advocate: Tips for Getting Started
04/12/2024

Featuring Rose Gerber, MS

Featuring Rose Gerber, MS
Patient advocate and cancer survivor Rose Gerber shares her experience in cancer patient advocacy and offers tips for those who wish to become advocates.
Patient advocate and cancer survivor Rose Gerber shares her experience in cancer patient advocacy and offers tips for those who wish to become advocates.
Patient advocate and cancer...
04/12/2024
Journal of Clinical Pathways
John Allan, MD, Weill Cornell Medicine
Conference Coverage
Comparing BTK Inhibitors for Frontline Chronic Lymphocytic Leukemia Treatment
04/10/2024

Featuring John Allan, MD

Featuring John Allan, MD
John Allan, MD, compares the use of different BTK inhibitors for the treatment of CLL in a frontline setting and discusses whether there is an optimal drug regimen to use among patients with CLL.
John Allan, MD, compares the use of different BTK inhibitors for the treatment of CLL in a frontline setting and discusses whether there is an optimal drug regimen to use among patients with CLL.
John Allan, MD, compares the use...
04/10/2024
Lymphoma, Leukemia & Myeloma Network
Erin Fox, PharmD
Videos
How Health Care Stakeholders in Oncology Can Prepare for and Manage Drug Shortages
04/08/2024

Featuring Erin Fox, PharmD

Featuring Erin Fox, PharmD
Erin Fox, PharmD, shares steps health care stakeholders can take to mitigate the impact of drug shortages on cancer care.
Erin Fox, PharmD, shares steps health care stakeholders can take to mitigate the impact of drug shortages on cancer care.
Erin Fox, PharmD, shares steps...
04/08/2024
Journal of Clinical Pathways
Robert Stillman, MA, RN
Videos
Best Practices in Care Team Communication Technology: Updates From NCCN 2024
04/06/2024

Featuring Robert Stillman, MA, RN

Featuring Robert Stillman, MA, RN ...
Robert Stillman, MA, RN, describes some of the latest innovations in health care communications technology and how providers can use these tools to improve their practices and provide value-based care.
Robert Stillman, MA, RN, describes some of the latest innovations in health care communications technology and how providers can use these tools to improve their practices and provide value-based care.
Robert Stillman, MA, RN,...
04/06/2024
Journal of Clinical Pathways

Newsfeed

News
Patients Often Favor Receiving Information About Cancer Therapy From the Oncologist
02/14/2023

Yvette C Terrie

Yvette C Terrie
According to findings from a patient-completed questionnaire published in the Journal of Cancer Education, among oncology patients, many favored receiving pertinent information directly from the oncologist regarding various facets of...
According to findings from a patient-completed questionnaire published in the Journal of Cancer Education, among oncology patients, many favored receiving pertinent information directly from the oncologist regarding various facets of...
According to findings from a...
02/14/2023
Journal of Clinical Pathways
Conference Coverage
Real-World Utilization and Comparative Effectiveness of Treatment Options for Cancer–Associated Venous Thromboembolism
06/04/2022

Janelle Bradley

Janelle Bradley
In the real-world setting, patients with cancer–associated venous thromboembolism remain on anticoagulation for a short period of time and DOACs and warfarin may be associated with better compliance than low molecular weight heparin.
In the real-world setting, patients with cancer–associated venous thromboembolism remain on anticoagulation for a short period of time and DOACs and warfarin may be associated with better compliance than low molecular weight heparin.
In the real-world setting,...
06/04/2022
Journal of Clinical Pathways
News
Immune Checkpoint Inhibitors May Have Been Used Inappropriately in Half of Study Patients with Advanced Cancer Who Were Near the End of Life
05/18/2022

Ellen Kurek

Ellen Kurek
Immune checkpoint inhibitors (ICIs) have been shown to extend progression-free survival and overall survival in patients with a variety of cancers, leading to increases in the systemic treatment of patients with advanced cancer who are near...
Immune checkpoint inhibitors (ICIs) have been shown to extend progression-free survival and overall survival in patients with a variety of cancers, leading to increases in the systemic treatment of patients with advanced cancer who are near...
Immune checkpoint inhibitors...
05/18/2022
Journal of Clinical Pathways
News
Early Palliative Care Reduces End-of-Life Health Care Costs
09/14/2021
Among patients with cancer, receipt of early palliative care reduced the average health system costs in the last month of life, especially through avoided hospitalizations.
Among patients with cancer, receipt of early palliative care reduced the average health system costs in the last month of life, especially through avoided hospitalizations.
Among patients with cancer,...
09/14/2021
Journal of Clinical Pathways
News
Impact of Performance Status on Outcomes Among Patients Receiving ICIs for Advanced Tumors
09/03/2021
Findings from a recent study suggest avoiding the use immune checkpoint inhibitors in patients with advanced malignancy and poor performance status, as the outcomes are poor in this group.
Findings from a recent study suggest avoiding the use immune checkpoint inhibitors in patients with advanced malignancy and poor performance status, as the outcomes are poor in this group.
Findings from a recent study...
09/03/2021
Journal of Clinical Pathways
News
Understanding the Stigmatization of Palliative Care Referral in Oncology
08/24/2021
Findings from a recent study suggest strategies for oncology clinicians to reduce the stigmatizing association of palliative care with end of life.
Findings from a recent study suggest strategies for oncology clinicians to reduce the stigmatizing association of palliative care with end of life.
Findings from a recent study...
08/24/2021
Journal of Clinical Pathways
Conference Coverage
Integrating Palliative Care Into Community Oncology Practice
04/29/2021
04/29/2021
Journal of Clinical Pathways
News
Variation in Treatment Planning of Radiation Therapy Procedures in the United States
02/19/2021
02/19/2021
Journal of Clinical Pathways
News
Clinician- vs Patient-Reported Performance Status for Predicting Patient Outcomes
02/11/2021
02/11/2021
Journal of Clinical Pathways
News
Predictive Model for at Home Care Among Patients With Solid-Tumor Malignancies
02/09/2021
02/09/2021
Journal of Clinical Pathways
Lalan Wilfong, MD
Videos
Balancing the Benefits and Risks of Value-Based Care Arrangements
05/16/2024
Lalan Wilfong, MD
Lalan Wilfong, MD, discusses his key takeaways from the Community Oncology Conference session on defining value-based care in oncology.
Lalan Wilfong, MD, discusses his key takeaways from the Community Oncology Conference session on defining value-based care in oncology.
Lalan Wilfong, MD, discusses his...
05/16/2024
Journal of Clinical Pathways
News
Patients With Breast Cancer Experience High Economic Burden and Lower HRQoL: Literature Review
05/15/2024
Grace Taylor, MS, MA
A systematic literature review summarizes the economic and health-related quality of life (HRQoL) outcomes experienced by patients with early-stage hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative...
A systematic literature review summarizes the economic and health-related quality of life (HRQoL) outcomes experienced by patients with early-stage hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative...
A systematic literature review...
05/15/2024
Journal of Clinical Pathways
News
The Economic Impact of Artificial Intelligence Usage in Screening Mammography
05/10/2024
Grace Taylor, MS, MA
Researchers evaluated the potential economic impact of artificial intelligence (AI) implementation on screening mammography from the perspective of treatment facilities and payers.
Researchers evaluated the potential economic impact of artificial intelligence (AI) implementation on screening mammography from the perspective of treatment facilities and payers.
Researchers evaluated the...
05/10/2024
Journal of Clinical Pathways
News
MorphoSys’ Myelofibrosis Drug Results Cast Doubt on Novartis Acquisition Deal
05/08/2024
Grace Taylor, MS, MA
MorphoSys’ $2.9 billion acquisition deal with Novartis may be in jeopardy due to reports regarding safety problems with its investigational myelofibrosis drug pelabresib.
MorphoSys’ $2.9 billion acquisition deal with Novartis may be in jeopardy due to reports regarding safety problems with its investigational myelofibrosis drug pelabresib.
MorphoSys’ $2.9 billion...
05/08/2024
Journal of Clinical Pathways
Julia Morton
Videos
The Impact of Technology at the Point of Care in Community Practice
05/01/2024
Julia Morton, senior vice president and general manager at Flatiron Health, talks about how recent developments in technology have impacted point-of-care solutions in community oncology.
Julia Morton, senior vice president and general manager at Flatiron Health, talks about how recent developments in technology have impacted point-of-care solutions in community oncology.
Julia Morton, senior vice...
05/01/2024
Journal of Clinical Pathways
Michael Serzan, MD
Videos
Recent Advancements in the Treatment of Renal Cell Carcinoma
04/24/2024

Featuring Michael Serzan, MD, Dana-Farber Cancer Institute

Featuring Michael Serzan, MD, Dana-Fa...
Michael Serzan, MD, highlights some of the latest advancements in the treatment of renal cell carcinoma.
Michael Serzan, MD, highlights some of the latest advancements in the treatment of renal cell carcinoma.
Michael Serzan, MD, highlights...
04/24/2024
Journal of Clinical Pathways
News
Dietary Recommendations for Patients With Myelofibrosis
04/22/2024

Grace Taylor

Grace Taylor
A balanced diet can help patients with myelofibrosis have more energy, better immune function, and more.
A balanced diet can help patients with myelofibrosis have more energy, better immune function, and more.
A balanced diet can help...
04/22/2024
Journal of Clinical Pathways
News
Study Estimates the Total Lifetime Cost of Treating Patients With CLL in the US
04/12/2024

Grace Taylor

Grace Taylor
A recent study by Farrukh Awan, MD, and colleagues estimated the total lifetime cost of treating patients with chronic lymphocytic leukemia in the US.
A recent study by Farrukh Awan, MD, and colleagues estimated the total lifetime cost of treating patients with chronic lymphocytic leukemia in the US.
A recent study by Farrukh Awan,...
04/12/2024
Journal of Clinical Pathways
Conference Coverage
Cybersecurity, Drug Shortages, and PBMs: Legislative Updates Impacting Oncology
04/12/2024

Grace Taylor

Grace Taylor
A group of health care industry experts recently shared legislative updates from Washington, DC, impacting oncology at the 2024 Community Oncology Conference.
A group of health care industry experts recently shared legislative updates from Washington, DC, impacting oncology at the 2024 Community Oncology Conference.
A group of health care industry...
04/12/2024
Journal of Clinical Pathways
Rose Gerber, MS
Videos
Becoming a Patient Advocate: Tips for Getting Started
04/12/2024

Featuring Rose Gerber, MS

Featuring Rose Gerber, MS
Patient advocate and cancer survivor Rose Gerber shares her experience in cancer patient advocacy and offers tips for those who wish to become advocates.
Patient advocate and cancer survivor Rose Gerber shares her experience in cancer patient advocacy and offers tips for those who wish to become advocates.
Patient advocate and cancer...
04/12/2024
Journal of Clinical Pathways

Interactive Features

Quiz
Quiz: Why is There Variation in Treatment Planning for Medicare Patients?
04/06/2021
04/06/2021
Journal of Clinical Pathways
Quiz
Quiz: NGS Testing Reimbursement for Cancer
10/06/2020
10/06/2020
Journal of Clinical Pathways
SPONSORED QUIZ BY SANOFI
Treatments in Multiple Myeloma
11/28/2022
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA...
11/28/2022
Journal of Clinical Pathways
Quiz
Quiz: Medicaid Insurance and Biomarker Testing in NSCLC
07/26/2022
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid...
07/26/2022
Journal of Clinical Pathways
Quiz
Quiz: Comparing the Cost of Regimens in Newly Diagnosed Multiple Myeloma
07/14/2022
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among...
07/14/2022
Journal of Clinical Pathways
Quiz
Quiz: Germline BRCA Testing in Ovarian Cancer
07/12/2022
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of...
07/12/2022
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of Margetuximab vs Trastuzumab for Breast Cancer
06/30/2022
True or False: Under a willingness-to-pay threshold of $100,000 per quality-adjusted life year, margetuximab plus chemotherapy is cost-effective compared to trastuzumab plus chemotherapy for patients with ERBB2–positive, advanced breast...
True or False: Under a willingness-to-pay threshold of $100,000 per quality-adjusted life year, margetuximab plus chemotherapy is cost-effective compared to trastuzumab plus chemotherapy for patients with ERBB2–positive, advanced breast...
True or False: Under a...
06/30/2022
Journal of Clinical Pathways
Quiz
Quiz: Real-World Treatment Patterns in Mantle Cell Lymphoma
06/28/2022
True or False: Bendamustine and rituximab was the most used frontline regimen for the treatment of MCL, while BTK inhibitors were the most used agents in later lines of therapy.
True or False: Bendamustine and rituximab was the most used frontline regimen for the treatment of MCL, while BTK inhibitors were the most used agents in later lines of therapy.
True or False: Bendamustine and...
06/28/2022
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of First-Line Treatments for Chronic Lymphocytic Leukemia
06/27/2022
True or False: Compared with venetoclax-plus-obinutuzumab, chemoimmunotherapies are associated with less health benefits at higher cost among patients with CLL.
True or False: Compared with venetoclax-plus-obinutuzumab, chemoimmunotherapies are associated with less health benefits at higher cost among patients with CLL.
True or False: Compared with...
06/27/2022
Journal of Clinical Pathways
Quiz
Quiz: Medicare Reimbursement in Head and Neck Surgical Oncology
05/25/2022
True or False: For the 37 most common head and neck surgical oncologic procedure codes considered as a group, U.S. Centers for Medicare & Medicaid Services reimbursement decreased from 2000 through 2020.
True or False: For the 37 most common head and neck surgical oncologic procedure codes considered as a group, U.S. Centers for Medicare & Medicaid Services reimbursement decreased from 2000 through 2020.
True or False: For the 37 most...
05/25/2022
Journal of Clinical Pathways
Quiz
Quiz: BTKi's Among Patients With Relapsed/Refractory MCL
05/10/2022
True or False: Among patients with relapsed/refractory mantle cell lymphoma, second-generation Bruton’s tyrosine kinase inhibitors (BTKIs) provide an additional progression-free survival benefit compared with ibrutinib
True or False: Among patients with relapsed/refractory mantle cell lymphoma, second-generation Bruton’s tyrosine kinase inhibitors (BTKIs) provide an additional progression-free survival benefit compared with ibrutinib
True or False: Among patients...
05/10/2022
Journal of Clinical Pathways
Quiz
Quiz: Biosimilar vs Referent Trastuzumab for ERBB2–Positive Breast Cancer
05/06/2022
True or False: HD201, a biosimilar to trastuzumab, demonstrated equivalence to referent trastuzumab in achieving a total pathological complete response and in safety in ERBB2–positive, early breast cancer.
True or False: HD201, a biosimilar to trastuzumab, demonstrated equivalence to referent trastuzumab in achieving a total pathological complete response and in safety in ERBB2–positive, early breast cancer.
True or False: HD201, a...
05/06/2022
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

JCP March/April 2024

Current Issue

April 2024
Volume 10
Issue 2
Current Issue
Issue Archive

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Special Reports

JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Winston Wong, PharmD
Gordon Kuntz
Robin T Zon, MD, FACP, FASCO
2021 Care Pathways Working Group
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Subscribe

Journal of Clinical Pathways Newsletter

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use

Advertisement

Advertisement